Generics Unit of Germany's Merck Gets Four Final Bids

Tuesday, 1 May 2007 | 12:55 AM ET

Merck, Germany's drugs and chemicals group, received four final bids for its generics drugs business, sources familiar with the situation said on Monday.

Actavis Group, Mylan Laboratories and Teva Pharmaceutical Industries submitted bids, while private equity firms Bain Capital and Apax Partners submitted a joint offer, sources said.

The bids were submitted by Monday's deadline, sources said, but details of the offers were not immediately available. Sources previously told Reuters the bids were expected to be about 4 billion euros ($5.46 billion).

Merck and the bidders could not be immediately reached for comment.

Merck said earlier this year it was reviewing a possible sale of the business and hired Bear Stearns as its adviser. After the offers are reviewed, the list of bidders will be narrowed to two finalists, with a final decision expected by mid-to-late-May, sources said.

Selling the business could help cut debt that Merck took on to help finance its purchase of Swiss group Serono, Europe's biggest biotech company.

Merck's generics business had sales of 1.8 billion euros in 2006, ranking the unit fourth in the world behind Teva, Novartis's Sandoz unit and Barr Pharmaceuticals .

  Price   Change %Change


Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Discussing Fed Chair Janet Yellen's view on the economy and the recovery, with Brian Levitt, Oppenheimer Funds senior economist; Jared Bernstein, Center on Budget and Policy Priorities senior fellow; and CNBC's Steve Liesman.

  • Discussing how the slump in social media stocks will impact the IPO of Chinese microblogging service Weibo, with Leena Rao, Tech Crunch Senior Editor; Max Wolff, Citizen VC chief economist and strategist; and CNBC's Seema Mody.

  • Weibo is akin to a hybrid of Twitter and Facebook. CNBC's Seema Mody digs into the market conditions in which the Chinese microblogging service will publicly debut.